Advertisement

Topics

Debiopharm Group Company Profile

13:09 EDT 24th March 2019 | BioPortfolio

Debio 025 is an oligopeptide that has some chemical features in common with cyclosporine A, but is devoid of its immunosuppressive pharmacological effects. It has a very potent inhibitory effect on HCV replication both in vitro and in vivo. Debio 025 has excellent antiviral activity against a broad range of genotypes (1, 2, 3 and 4); a high barrier to the development of resistance; and the possibility for once daily dosing. It is expected to have a superior safety and efficacy profile to standard of care, and to be efficacious in patients not responding to the standard treatment.


News Articles [704 Associated News Articles listed on BioPortfolio]

Debiopharm begins afabicin trial for staphylococcal infections

Debiopharm International has initiated a Phase II clinical trial of its antibiotic afabicin (Debio 1450) to treat staphylococcal infections at bones and...Read More... The post Debiopharm begins afa...

Debiopharm Group Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13082018] Prices from USD $250

SummaryDebiopharm Group Debiopharm is a biopharmaceutical company that develops biologics and small molecule drug candidates. The company's product portfolio includes eloxatin, elplat, dacotin, dacpla...

Debiopharm Innovation Fund SA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 24092018] Prices from USD $250

SummaryDebiopharm Innovation Fund SA Debiopharm Diagnostics, formerly Debiopharm Diagnostics SA, a subsidiary of Debiopharm Group, is a patient care investment company that offers drug investments and...

Debiopharm Innovation Fund SA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 06122018] Prices from USD $250

SummaryDebiopharm Innovation Fund SA Debiopharm Innovation, formerly Debiopharm Diagnostics SA, a subsidiary of Debiopharm Group, is a patient care investment company that offers drug investments and ...

PTV News: Jan 8, 2010

Top stories on January 8th, 2010: Huge potential: Vivus obesity drug cuts sleep apnea too Lundbeck investigated by EU over generic claims Second stab: Debiopharm to develop Pfizer failure Cyclace...

Debiopharm International SA Medical Equipment Deals and Alliances Profile [Report Updated: 18072018] Prices from USD $250

SummaryDebiopharm International SA Debiopharm, a subsidiary of Debiopharm Group is a biopharmaceutical company that develops prescription drugs. The company offers a range of licensing and drug develo...

Debiopharm International SA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummaryDebiopharm International SA Debiopharm, a subsidiary of Debiopharm Group is a biopharmaceutical company that develops prescription drugs. The company offers a range of licensing and drug develo...

Zur Rose Group announces result of rights take-up

EQS Group-News: Zur Rose Group AG / Key word(s): Capital Increase 28.11.2018 / 17:35 Under the following link, you will find a press release of the Zur Rose Group.   https://zurrosegrou...

Drugs and Medications [0 Results]

None

PubMed Articles [1688 Associated PubMed Articles listed on BioPortfolio]

Isolation and exploitation of minority: Game theoretical analysis.

We investigate various group-size distributions occurring in a situation where each group's resource is exposed to appropriation by other groups. The amount of appropriation depends on the size differ...

Reply to readers (Manuscript ID: HEP-18-1297).

In our preliminary experiment, we divided patients into 3 groups, 10 patients in each group. Group A received standard medicine treatment (SMT) only. Group B was treated with allogeneic bone marrow-de...

Characteristics of 2017 GOLD COPD group A: a multicenter cross-sectional CAP study in Japan.

The 2017 GOLD ABCD classification shifts patients from groups C-D to A-B. Group A was the most widely distributed group in several studies. It would be useful to understand the characteristics for gro...

Appearance of large scavenger receptor A-positive cells in peripheral blood: A potential risk factor for severe exacerbation of chronic obstructive pulmonary disease.

Fresh peripheral blood (PB) samples from 432 outpatients with stable chronic obstructive pulmonary disease (COPD) were examined. Patients were classified into Group A (large SRA cells were undetected)...

Comparison of Congenital Malformations among Babies Born after Administration of Letrozole or Clomiphene Citrate for Infertility Treatment in a Korean Cohort.

This retrospective study investigated and compared the incidence of congenital foetal anomalies after letrozole versus clomiphene citrate (CC) administration for infertility treatment. Data from 142 n...

Clinical Trials [4373 Associated Clinical Trials listed on BioPortfolio]

MAC-cbt Group Therapy for Adults With ADHD

The study is developed to validate a new short psychotherapeutic group treatment for adults with ADHD diagnosis. The participants will be treated in a monocentric, parallel group randomize...

The Influence of Hypotensive Drugs on Mineral Status in Experimental and Clinical Studies

The aim of the study was to evaluate the effects of hypotensive treatment combined with a higher zinc supply in the diet and supplements on the mineral status and selected biochemical para...

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants

The purpose of this study is to evaluate the safety and tolerability of single oral doses of TAK-828 in healthy non-Japanese and Japanese participants.

Ultrasound and Exercises in Knee Osteoarthritis

The aim of this investigation is to compare the effects of continuous (CUS) and pulsed (PUS) ultrasound associated with a program of exercises on pain, range of motion, muscle strength, fu...

Technical Development of Multi-Parametric Renocerebral MRI

The purpose of the study is to investigate the associations of the age-related changes in the brain, kidneys and cognitive performance in healthy adults by utilizing multiple anatomic and ...

Companies [1656 Associated Companies listed on BioPortfolio]

The Debiopharm Group

Debiopharm Group(TM) (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-l...

Debiopharm Galenic Unit

Debiopharm, Debiovision, Debioinnovation, Debio R.P. and Debioclinic form an established group of five complementary and synergistic companies. Together, they provide drug development expertise and kn...

Debiopharm Group

Debio 025 is an oligopeptide that has some chemical features in common with cyclosporine A, but is devoid of its immunosuppressive pharmacological effects. It has a very potent inhibitory effect o...

W2 Group, Inc.

W2 Group is a global marketing services ecosystem that helps CMOs in their new role as builders of communities and content aggregators. W2 Group companies, including Digital ...

PharmEvo (Pvt.) Ltd.

PharmEvo is backed by a reputable corporate group with a history of successful business ventures spread over 30 years. The group made its debut in 1971, with the sales and marketing of prestigious bra...

More Information about "Debiopharm Group" on BioPortfolio

We have published hundreds of Debiopharm Group news stories on BioPortfolio along with dozens of Debiopharm Group Clinical Trials and PubMed Articles about Debiopharm Group for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Debiopharm Group Companies in our database. You can also find out about relevant Debiopharm Group Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record